Immunological mechanisms explaining the role of IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines, Vitamin C, hydroxychloroquine, ivermectin and azithromycin

Vini Arumugham
Apr 2020
vinucubeacc@gmail.com

Abstract

A novel coronavirus, SARS-CoV-2 was identified in Wuhan, China. The disease caused by the virus can range in severity from asymptomatic to acute respiratory distress syndrome (ARDS) and death.

Primary dengue infection results in IgE mediated sensitization against dengue virus (DENV) proteins. These IgE bind to receptors on mast cells. Upon subsequent exposure to the antigen recognized by the IgE, mast cell degranulation occurs releasing mediators such as histamine. Therefore secondary dengue infection results in urticaria, increased vascular permeability, hypotension, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). A case of “slow rolling anaphylaxis”.

Since vaccines contain animal proteins derived from animals infected with any number of viral diseases, one could develop IgE mediated sensitization to numerous viral proteins including coronavirus proteins. Therefore, receipt of such vaccines acts like a dengue “primary infection”. It results in IgE mediated sensitization directed against coronavirus proteins. Once sensitized, a SARS-CoV-2 infection therefore now becomes the equivalent of a secondary dengue infection and similarly can have a severe course for the same reason - IgE mediated mast cell degranulation and the immune cascade that follows.

There are many common observations between COVID-19 and dengue. Elevated levels of ferritin, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), D-dimer, coagulopathy, urticaria and ARDS are reported in both diseases.

There are many indicators that mast cell degranulation and histamine release may have a major role in COVID-19 and dengue severity. Mast cell stabilizers, antihistamines, Vitamin C, HCQ, azithromycin, ivermectin may address different aspects of this cascade and thus reduce disease severity. Disease mechanisms and immunopathology must be understood. Focusing on anti-viral action of drugs alone could be counter productive. For example, CQ had no effect on viraemia but decreased cases of DHF.

Introduction

A novel coronavirus, now named SARS-CoV-2 was identified in hospitalized patients in Wuhan, China, in December 2019. The disease caused by the virus, now named COVID-19, can range in severity from asymptomatic to acute respiratory distress syndrome (ARDS) and death.

Discussion

Primary dengue infection results in immunoglobulin E (IgE) mediated sensitization directed against dengue virus (DENV) proteins (1,2). These IgE antibodies bind to high affinity FcεRI receptors on mast cells. Upon subsequent exposure to the antigen recognized by the IgE, cross-linking of antibodies
will result in mast cell degranulation and release of mediators such as histamine. The same process occurs with IgE bound to basophils. Therefore secondary dengue infection results in such mast cell degranulation, histamine release, leading to urticaria, increased vascular permeability, hypotension, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). It can be viewed as a type 1 immediate hypersensitivity reaction with the difference that the antigen exposure is not a step function (as in say food allergy) but a ramp function as the viral replication ramps up over a few days. As a result, we have a “slow rolling anaphylaxis”.

Influenza vaccines cause IgE mediated sensitization to influenza viral proteins (3–7). Upon subsequent infection with influenza virus, we have mast cell degranulation as in the case of dengue. The course of the infection is worse because we have a viral infection concurrent with an allergic reaction. As the viral load increases, so will the severity of the allergic reaction, leading to influenza shock syndrome (ISS) (8).

This concept can be generalized. Any population where a new virus/bacteria is introduced, can suffer severe disease if the population has prior IgE mediated sensitization directed against epitopes that have homology to epitopes in the novel pathogen. In nature, IgE mediated sensitization is directed against helminth/parasite antigens. However, now, for the vast majority of the world’s population, helminth and parasite infections are rare. The main cause of IgE mediated sensitization is vaccines (9). Therefore, upon reports of SARS-CoV-2, protein sequence analysis was performed comparing SARS-CoV-2 proteome to the proteomes of organisms used in vaccine manufacturing. The strongest match was to a pig spike protein (from a coronavirus infected pig). Accession number QGV12786 vs. QHD43416.1 for SARS-CoV-2. Detailed BLASTP (10) results are included in a section below. Not surprisingly, that pig spike protein also has high homology to SARS and MERS virus spike proteins.

Since vaccines contain animal proteins derived from pigs (porcine gelatin), cows (bovine serum albumin) infected with any number of viral diseases, one could develop IgE mediated sensitization to numerous viral proteins including coronavirus proteins. We have entire, viable porcine circoviruses in the rotavirus vaccines, for example (11). And of course, this is not limited to porcine material. Vaccine manufacturing derives materials from bovine, chicken and other animal sources as well. Therefore, receipt of such vaccines acts like a dengue “primary infection”. It results in IgE mediated sensitization directed against coronavirus proteins. Once sensitized, a SARS-CoV-2 infection therefore now becomes the equivalent of a secondary dengue infection and similarly can have a severe course for the same reason - IgE mediated mast cell degranulation and the cascade that follows.

Rangwani (12,13) provides additional evidence on the role of mast cells in COVID-19.

Similarity between COVID-19 and dengue

There are now multiple reports from dengue endemic areas that COVID-19 is being mistakenly diagnosed as dengue (14,15). Given the reasons above, there is good reason to expect such similarity.

In COVID-19, elevated levels of ferritin (16), interleukin-6 (IL-6)(16), vascular endothelial growth factor (VEGF) (17) and D-dimer (18), have been reported. Elevated levels of ferritin (19), IL-6 (20) , VEGF (21) and D-dimer (22,21) are also reported with dengue infection. Coagulopathy is reported in both COVID-19 (18) and dengue (20). Urticaria is reported in both (14,23,24). ARDS is common in COVID-19 (25). ARDS is also described in dengue patients (26).
IgE mediated sensitization to coronavirus will result in mast cell degranulation when exposed to the SARS-CoV-2 proteins. Specifically, mast cell degranulation by cross-linking of IgE bound to high affinity FcεRI receptors on the surface of mast cells results in the release of many mediators including histamine and ferritin (27). Histamine promotes release of IL-6 (28). Elevated levels of ferritin and IL-6 are predictors for fatality in COVID-19 (16). Such IgE triggered degranulation also results in the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) (29). This results in activation of the coagulation system and elevated D-dimer levels (30). The same cascade applies to secondary dengue infection.

Such striking similarity is to be expected because of the same underlying immunological mechanisms involved in both diseases.

The parasite connection

In nature, the main role of the IgE antibody is defending against parasites. Many parasites in nature enter via the skin (malaria, hookworm). DENV is injected via the skin by a mosquito bite. Vaccines contain viral proteins derived from coronavirus infected animals. These vaccines injected through the skin, program the immune system to recognize these viral proteins (and thus the viruses) as parasites (IgE mediated sensitization). The immune system therefore inappropriately mounts an anti-parasite response against the virus upon infection, along with an anti-viral response. So it is not surprising that some anti-parasitic medications (and anti allergy medications) seem to help by suppressing the inappropriate part of the immune response.

Parasites have evolved to produce numerous decoy proteins to confuse the human immune system as an evasive measure (31). As a result, the immune system is forced to produce IgE directed against numerous proteins thus diluting the response against parasite-specific proteins. Therefore in a population where parasite infections are common, IgE mediated response to any specific protein such as viral proteins would be weak. Now, with parasite infections being rare, this protection is lost. We have strong IgE mediated responses against viral proteins, once sensitized.

Hydroxychloroquine (HCQ), chloroquine (CQ) and ivermectin (IMC) are anti-parasite medications. There are indications that they may benefit in COVID-19 (32,33) and dengue (34). There is controversy over the antiviral activity of these drugs.

Both HCQ (35) amd IMC (36) have been shown to reduce IgE levels. So it does not come as a surprise that these anti-parasite drugs have beneficial effect on viral diseases involving IgE mediated immunopathological changes. IgE is now also involved in allergies. Anti-allergy medications also can therefore help in these diseases (24).

The Dengvaxia vaccine causes simultaneous IgE mediated sensitization against all four DENV serotypes. A natural infection will cause IgE mediated sensitization directed against only one DENV serotype at a time. A secondary infection by the same serotype virus will result in severe disease. Therefore, as expected, the probability of a severe secondary infection following the Dengvaxia vaccine is much higher thus resulting in more deaths among the vaccinated. The details were previously described (37).

The exact same failure was observed in experimental SARS-CoV vaccine in mice (38). The mice developed IgE mediated sensitization to the SARS-CoV proteins following vaccination. The mice
developed “Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components” when subsequently challenged with the virus.

So we have a consistent, repeating pattern of first injected exposure to SARS-CoV, dengue, influenza or coronavirus proteins resulting in IgE mediated sensitization directed against the viral proteins. Subsequent exposure to the viruses results in severe disease due to a viral infection concurrent with an allergic reaction. The first injection in the case of dengue virus can be a natural mosquito bite. In all other cases and in the case of the dengue vaccines, IgE mediated sensitization is iatrogenic and preventable.

**Potential Treatments**

Mast cell stabilizers work at the main source and can prevent release of histamine, elevation of ferritin, IL-6, VEGF, D-dimer levels, etc. Neutrophils recruited to the infection site release histamine (39). Antihistamines can block some of the effects of histamine.

Vitamin C has an antihistamine effect (40). Hydroxychloroquine improves IgE mediated asthma (35). Azithromycin has an anti-inflammatory effect on histamine induced inflammation (41). For these reasons, Vitamin C, hydroxychloroquine and azithromycin can help in COVID-19 (32,33).

**Conclusion**

COVID-19 is an iatrogenic disease caused by IgE mediated sensitization to coronavirus proteins present in vaccines containing components derived from infected animals. There are many indicators that mast cell degranulation and histamine release may have a major role in COVID-19 and dengue infection severity. Mast cell stabilizers, antihistamines, Vitamin C, HCQ, azithromycin, ivermectin may address different aspects of this cascade and thus reduce disease severity. Disease mechanisms and immunopathology must be understood. Focusing on anti-viral action of drugs alone could be counter productive. For example, CQ had no effect on viraemia but decreased cases of DHF (34).

**BLASTP detailed results**

QHD43416.1 surface glycoprotein [Severe acute respiratory syndrome coronavirus 2] vs. porcine spike protein (from a coronavirus infected pig)
### Alignment statistics for match #1

| Score | Expect | Method                        | Identities | Positives | Gaps |
|-------|--------|-------------------------------|------------|-----------|------|
| 322 bits(824) | 1e-89 | Compositional matrix adjust. | 234/765(31%) | 361/765(47%) | 101/765(13%) |

#### Query 521

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| P  | G  | +  | +  | C  | +  | G  |

#### Sbjct 632

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| P  | K  | +  | +  | +  | +  | C  |

#### Query 581

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | N  | +  |

#### Sbjct 691

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | +  | +  | +  | T  |

#### Query 641

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| F  | H  | N  | +  | C  | +  | G  |

#### Sbjct 733

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| G  | F  | Y  | +  | +  | +  | T  |

#### Query 697

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |

#### Sbjct 778

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| V  | +  | +  | +  | +  | +  | +  |

#### Query 757

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |

#### Sbjct 827

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | +  | +  | +  | +  |

#### Query 811

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |

#### Sbjct 887

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |

#### Query 867

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |

#### Sbjct 947

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| +  | +  | +  | T  | +  | +  | +  |
While the highest homology was to the pig spike protein above, there is also strong homology to other common vaccine components such as the *Bordetella pertussis* protein below:

orf1ab polyprotein [Severe acute respiratory syndrome coronavirus 2] vs. *B. pertussis*

putative DNA helicase [*Bordetella pertussis*]

CPP87293.1 394 1

Alignment statistics for match #1

| Score          | Expect | Method | Identities | Positives | Gaps |
|----------------|--------|--------|------------|-----------|------|
| 55.5 bits(132) | 1e-05  | Composition-based stats. | 89/356(25%) | 140/356(39%) | 61/356(17%) |

Query 5604

LQGPPGTGKSHFA -- IGLALYYPARIVTACSHAADVCEKALYLPIDKCSRIIPAR 5661

LQGPPG GK++ + L L R++ + SH A++ L + L+ L + + A+

Sbjct 8

LQGPPGAKGKTYGSRVLLQQLLRAAGRRVAVSSNSHAINNFL--RGLERLAEREGFALRGA 66

Query 5662

ARVE-CFDKFKVNSTLEQYVFCT--VNALP--ETTADIVVEDEISA 5703

A++E FD V+ Q V T + A P E D + DE

Sbjct 67

KSTSAGDDSCLGGAQIEVDVFNDKVDPAHQLVAGTAWLFARPEFEQAFDYLFVEADQGG 126

Query 5704

TNYDLSVVNARLRKAKHYVYIDPAQLPAPRTLLTKGTEPEYNSCVRLMTKIGPD--MF 5761

+ + + + A++ + + G Q P G + + + +

Sbjct 127

SLANLVMAGQ--CARIVGILGQMQLQGQGTHPGRSYESALVYLDGQATIAASQVF 184

Query 5762

LTCTRCPAEPDVTDSLVYDNLKKAHDKSAQCF----------KMFYKGV-------ITHDVS 5809

L T R EI + S +YD +L+A ++ G+ + HD +

Sbjct 185

KSTSAGDDSCLGGAQIEVDVFNDKVDPAHQLVAGTAWLFARPEFEQAFDYLFVEADQGG 126

Query 5804

SAINRPQIGVREV----FTRNPWARKA----------VFISPYNQNAVSLK--GLP 5853

+ +R + + V E L R +A + + F++PYN Q L G

Sbjct 63

KLETGKAVITSGGKLKAKYVIHAVGPIWRGGSCNTEELVACLALIAATLS 122

Query 5854

TQTVSSQGSEYDVFQFITQTTETAHSC--------NVNRFNVATRAKVGILCIMS 5901

L TVD Q G E VI + T + + NR NVAI+RA+ + + S

Sbjct 305

VGTVDKFQFQQAEQVIVSMATSSGDYLDLEDLEFLFSRNNLVAINSRATLAILV 360

orf1ab polyprotein [Severe acute respiratory syndrome coronavirus 2] vs. *C. tetani*

*ADP*-ribose-binding protein [*Clostridium tetani*]

WP_023438321.1 179 1

- See 4 more title(s)

Alignment statistics for match #1

| Score          | Expect | Method | Identities | Positives | Gaps |
|----------------|--------|--------|------------|-----------|------|
| 41.6 bits(96) | 0.077  | Composition-based stats. | 43/147(29%) | 73/147(49%) | 13/147(8%) |

Query 1036

DNVYKNADIKEVEAKKVPKTVVPVNAANVLYKKGVAGALNKATNNAMQSVERSDDYIATNG 1095

+ + I DI E++ +VNAAN L GGGV GA+++KA + + E + I+ G

Sbjct 7

NKISIIKGDITKESVADA-----IVNAANSVLLGGGGVDGAIHKAGGSQILKECKEIIKISG 62

Query 1096

PLKVGGSCVLSGHNL--AKCHLHVGVPNVVKGE--DIQLLKSAENF------NQHEVLAA 1146

L+ G + + SG L AK+ +H VGP G + LL + Y N + +

Sbjct 63

KLETGKAVITSGGKLKAKYVIHAVGPIWRGGSCNEETLACNYINSNLAKEDKDIKIAF 122

Query 1147

PLSAGIFGADPIHSLRVCVDTVRN 1173

P +S G+G +++++ T++ N+

Sbjct 123

PNISTGVYGFQPQLAVKIVKFTMKENI 149
References

1. Míguez-Burbano MJ, Jaramillo CA, Palmer CJ, Shor-Posner G, Velásquez LS, Lai H, et al. Total Immunoglobulin E Levels and Dengue Infection on San Andrés Island, Colombia. Clin Diagn Lab Immunol. 1999 Jul 1;6(4):624 LP – 626.

2. Koraka P, Murgue B, Deparis X, Setiati TE, Suharti C, Van Gorp ECM, et al. Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. J Med Virol. 2003;70(1):91–8.

3. Smith-Norowitz Ta, Wong D, Kusonruksa M, Norowitz KB, Joks R, Durkin HG, et al. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int J Med Sci. 2011;8(3):239–44.

4. Davidsson A, Eriksson JC, Rudblad S, Brokstad KA. Influenza Specific Serum IgE is Present in Non-Allergic Subjects. Scand J Immunol. 2005 Dec;62(6):560–1.

5. Nakayama T, Kumagai T, Nishimura N, Ozaki T, Okafuji T, Suzuki E, et al. Seasonal split influenza vaccine induced IgE sensitization against influenza vaccine. Vaccine. 2015 Nov 9;33(45):6099–105.

6. Nagao M, Fujisawa T, Ihara T, Kino Y. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis. J Allergy Clin Immunol. United States; 2016 Mar;137(3):861–7.

7. Kim MJ, Shim DH, Cha H-R, Kim CB, Kim SY, Park JH, et al. Delayed-Onset Anaphylaxis Caused by IgE Response to Influenza Vaccination. Allergy Asthma Immunol Res. 2020 Mar;12(2):359.

8. Arumugham V. Influenza vaccines and dengue-like disease [Internet]. The BMJ. 2018. Available from: https://www.bmj.com/content/360/bmj.k1378/rr-15

9. Arumugham V. Evidence that Food Proteins in Vaccines Cause the Development of Food Allergies and Its Implications for Vaccine Policy. J Dev Drugs. OMICS International; 2015 Oct;04(04):1–3.

10. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389–402.

11. CDC, Ncird. Centers for Disease Control and Prevention Epidemiology and Prevention of Vaccine-Preventable Diseases,13th Edition [Internet]. [cited 2020 Jan 17]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/appdx-full-b.pdf

12. Rangwani C. Possible Relationship of Mast Cell Degranulation and Cytokine Storm related COVID19 Morbidity in Young and Old Population. SSRN Electron J. 2020 Mar 28;
13. Rangwani C. The Wisdom of Treating Covid19 As an Hyperallergenic Response. Mast Cell and Cytokine Storm Related Morbidity - Perspective, Review and Hypothesis. SSRN Electron J. 2020 Apr 2;

14. joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for Dengue [Internet]. 2020 [cited 2020 Apr 9]. Available from: https://doi.org/10.1016/j.jaad.2020.03.036

15. Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, et al. Covert COVID-19 and false-positive dengue serology in Singapore. The Lancet Infectious Diseases. Lancet Publishing Group; 2020.

16. Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. Correspondence COVID-19: consider cytokine storm syndromes and. Lancet. Elsevier Ltd; 2020 Mar 28;6736(20):19–20.

17. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology. Academic Press Inc.; 2020.

18. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. Massachusetts Medical Society; 2020 Apr 8;NEJMc2007575.

19. van de Weg CAM, Huits RMHG, Pannuti CS, Brouns RM, van den Berg RWA, van den Ham HJ, et al. Hyperferritinaemia in Dengue Virus Infected Patients Is Associated with Immune Activation and Coagulation Disturbances. PLoS Negl Trop Dis. Public Library of Science; 2014;8(10).

20. Rachman A, Rinaldi I. Coagulopathy in dengue infection and the role of interleukin-6. Acta medica Indonesiana. 2006. p. 105–8.

21. Mutiara, Koh SCL, Bachtiar A, Hariman H. The vascular endothelium in patients with dengue haemorrhagic fever. Open Access Maced J Med Sci. Open Access Macedonian Journal of Medical Sciences; 2019 Jul 30;7(14):2221–5.

22. Setrkrasing K, Bongsebandhu-Phubhakdi C, Voraphani N, Pancharoen C, Thisyakorn U, Thisyakorn C. D-dimer as an indicator of dengue severity.

23. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol. Wiley; 2020 Mar 26;

24. M C. A case of dengue fever presenting with acute urticaria. Asian Pacific J Allergy Immunol. Allergy, Asthma, and Immunology Association of Thailand; 2019;

25. Goh KJ, Choong MC, Cheong EH, Kalimuddin S, Duu Wen S, Phua GC, et al. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection. Ann Acad Med Singapore. NLM (Medline); 2020 Jan 1;49(1):1–9.
26. Sen MK, Ojha UC, Chakrabarti S, Suri JC. Dengue hemorrhagic fever (DHF) presenting with ARDS. Indian J Chest Dis Allied Sci. 41(2):115–9.

27. Ward BR, Hicks M, Johnson J-M, Myo YPA. Ferritin Particles Accumulate in Human Mast Cell Secretory Granules and Are Released upon FcεRI-mediated Activation. J Allergy Clin Immunol. Elsevier BV; 2018 Feb 1;141(2):AB229.

28. Park IH, Um JY, Cho JS, Lee SH, Lee SH, Lee HM. Histamine promotes the release of interleukin-6 via the H1R/p38 and NF-κB pathways in nasal fibroblasts. Allergy, Asthma Immunol Res. Korean Academy of Asthma, Allergy and Clinical Immunology; 2014;6(6):567–72.

29. Okayama Y, Kobayashi H, Ashman LK, Dobashi K, Nakazawa T, Holgate ST, et al. Human lung mast cells are enriched in the capacity to produce granulocyte-macrophage colony-stimulating factor in response to IgE-dependent stimulation. Eur J Immunol. 1998 Feb;28(2):708–15.

30. Criado PR, Antinori LCL, Maruta CW, dos Reis VMS. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol. Sociedade Brasileira de Dermatologia; 2013 May;88(3):355–60.

31. Chauhan VM, Scurr DJ, Christie T, Telford G, Aylott JW, Pritchard DI. The physicochemical fingerprint of Necator americanus. Fujiwara RT, editor. PLoS Negl Trop Dis. Public Library of Science; 2017 Dec 7;11(12):e0005971.

32. GAUTRET P, LAGIER JC, PAROLA P, HOANG VT, MEDDED L, MAILHE M, et al. Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. medRxiv. Cold Spring Harbor Laboratory Press; 2020 Mar 20;2020.03.16.20037135.

33. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. Cold Spring Harbor Laboratory Press; 2020 Mar 31;2020.03.22.20040758.

34. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults. Halstead SB, editor. PLoS Negl Trop Dis. Public Library of Science; 2010 Aug 10;4(8):e785.

35. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol. Mosby Inc.; 1998 Aug 1;102(2):198–203.

36. Steel C, Lujan-Trangay A, Gonzalez-Peralta C, Zea-Flores G, Nutman TB. Immunologic Responses to Repeated Ivermectin Treatment in Patients with Onchocerciasis. The Journal of Infectious Diseases. Oxford University Press; p. 581–7.
37. Arumugham V. Irrational dengue vaccine designs that ignore IgE and IgG4 mediated effects are destined to follow in Dengvaxia’s disastrous direction? [Internet]. 2018. Available from: https://doi.org/10.5281/zenodo.1476291

38. Tseng C Te, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. Public Library of Science; 2012 Apr 20;7(4).

39. Xu X, Zhang D, Zhang H, Wolters PJ, Killeen NP, Sullivan BM, et al. Neutrophil histamine contributes to inflammation in mycoplasma pneumonia. J Exp Med. The Rockefeller University Press; 2006 Dec 25;203(13):2907–17.

40. Johnston CS, Martin LJ, Cai X. Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis. In: Journal of the American College of Nutrition. 1992. p. 172–6.

41. Ersoy B, Aktan B, Kilic K, Sakat MS, Sipal S. The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in Guinea pigs. J Laryngol Otol. Cambridge University Press; 2018 Jul 1;132(7):579–83.